American Society of Hematology

Fig. 3.

$Fig. 3. Heterogeneous IL-6 production by myeloma cells. / BMMC were stimulated with 1 μg/mL LPS and 2 μM monensin. Cells were fixed, permeabilized, stained with PE-conjugated anti–IL-6 mAb and FITC-conjugated anti–syndecan-1 mAb, and analyzed with use of flow cytometry. The proportion of IL-6–producing cells among syndecan-1+ BMMC was calculated as follows: (percentage of IL-6–producing syndecan-1+ BMMC divided by percentage of syndecan-1+ BMMC) times 100. Patients with primary refractory disease and resistant relapse had the highest proportion values. P < .005 compared with patients with MGUS.$

Heterogeneous IL-6 production by myeloma cells.

BMMC were stimulated with 1 μg/mL LPS and 2 μM monensin. Cells were fixed, permeabilized, stained with PE-conjugated anti–IL-6 mAb and FITC-conjugated anti–syndecan-1 mAb, and analyzed with use of flow cytometry. The proportion of IL-6–producing cells among syndecan-1⁺ BMMC was calculated as follows: (percentage of IL-6–producing syndecan-1⁺ BMMC divided by percentage of syndecan-1⁺ BMMC) times 100. Patients with primary refractory disease and resistant relapse had the highest proportion values. P < .005 compared with patients with MGUS.

This Feature Is Available To Subscribers Only